Clinical trial
Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants
NCT02745990 is registered in ClinicalTrials.gov with Huiqing Sun as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants
- Lead sponsor
- Huiqing Sun
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- May 31, 2016
- Completion date
- December 31, 2022
- Enrollment
- 440 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.